Markets:

Overview

News

Currencies

International

Treasuries

Abbott Laboratories (NY:ABT)

110.12 +0.82 (+0.75%)

Streaming Delayed Price Updated: 12:01 PM EST, Feb 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Abbott Laboratories

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

52 53 Next >

How Is The Market Feeling About Abbott Laboratories? ↗

February 28, 2023

Abbott Laboratories's (NYSE:ABT) short percent of float has risen 11.43% since its last report. The company recently reported that it has 13.19 million shares sold short, which is 0.78% of all regular...

Via Benzinga

Should Abbott and DexCom Investors Be Worried About Apple's Latest News? ↗

February 28, 2023

The continuous glucose monitoring market could heat up.

Via The Motley Fool

Better Dividend Stock: Abbott Laboratories or Medtronic? ↗

February 27, 2023

One of these top dividend stocks is a far more compelling buy today.

Via The Motley Fool

Top 5 Health Care Stocks That May Rocket Higher In Q1 2023 ↗

February 27, 2023

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Via Benzinga

Better Buy: Abbott Laboratories or DexCom Stock? ↗

February 24, 2023

Both stocks should benefit from the growth in diabetes care.

Via The Motley Fool

Why Abbott Laboratories Stock Sank Today ↗

February 22, 2023

The company's glucose monitoring business might come under some serious pressure.

Via The Motley Fool

Why Cardiovascular Systems Stock Is Soaring Today ↗

February 09, 2023

The medtech company has agreed to a buyout offer from Abbott Laboratories.

Via The Motley Fool

Is This Dividend King a Buy for Income Investors? ↗

February 07, 2023

This healthcare company has one of the most established payouts in its sector.

Via The Motley Fool

What Does Apple Have To Do With DexCom Stock Trading Lower? ↗

February 22, 2023

DexCom shares (NASDAQ: DXCM) are trading lower on Wednesday following a report that Apple Inc (NASDAQ: AAPL) is making progress on no-prick glucose tracking for its Watch.

Via Benzinga

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO), Cardiovascular Systems, Inc. (Nasdaq – CSII)

February 22, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

3 Top Dividend Kings to Buy for the Long Haul ↗

February 20, 2023

These companies have more than 150 years of dividend growth between them.

Via The Motley Fool

2 Exceptional Growth Stocks Billionaires Keep Buying With Both Hands ↗

February 20, 2023

A poor performance from the broad market didn't stop these billionaire hedge fund managers from placing big bets on three supercharged growth stocks.

Via The Motley Fool

Interview With David Rolfe of Wedgewood Partners ↗

February 17, 2023

Motley Fool analyst John Rotonti recently seized the opportunity to interview David Rolfe.

Via The Motley Fool

I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said. ↗

February 17, 2023

We asked ChatGPT to name various types of stocks to buy. Can the latest artificial intelligence craze get things right?

Via InvestorPlace

How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula

February 17, 2023

New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors.

Via MarketBeat

7 Hot Healthcare Stocks With the Potential to Outperform ↗

February 15, 2023

These healthcare stocks to buy now have the potential to outperform the market over the long-term because their businesses are strong.

Via InvestorPlace

Which Healthcare Stock Is a Better Pick in 2023? ↗

February 14, 2023

With a potential recession on the horizon, healthcare stocks could be good picks for investors. Which of these three is best?

Via InvestorPlace

February 14, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Better Buy: Johnson & Johnson or AbbVie? ↗

February 14, 2023

The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead.

Via The Motley Fool

Candy? Flowers? These Top Stocks Offer You Something Even Sweeter ↗

February 14, 2023

These stocks may reward you over time.

Via The Motley Fool

The 7 Most Undervalued Dividend Aristocrats to Buy ↗

February 13, 2023

With so many uncertainties ahead, investors may take comfort in the stability of the most undervalued dividend aristocrats to buy.

Via InvestorPlace

Abbott-Cardiovascular Systems Acquisition Could Further Add Uncertainty Over Surmodics' Product: Analyst Downgrades Stock ↗

February 13, 2023

Via Benzinga

Cardiovascular Systems (NASDAQ: CSII) Enters Into Agreement to be Acquired By Abbott Labs (NYSE: ABT) For $890 Million

February 09, 2023

Cardiovascular Systems, Inc. (NASDAQ: CSII) is engaged as a medical device company, which is focused on the research, development and

Via Spotlight Growth

Why Is Cardiovascular Systems (CSII) Stock Up 48% Today? ↗

February 09, 2023

Cardiovascular Systems (CSII) stock is rising higher on Thursday following news that Abbott (ABT) intends to acquire the company.

Via InvestorPlace

Abbott Adds Complementary Technologies To Its Vascular Offering Via Cardiovascular Systems Deal For $890M ↗

February 09, 2023

Via Benzinga

3 Dividend Stocks That Will Hold Up No Matter the Market Conditions ↗

February 08, 2023

These stocks could boost your portfolio in bear markets and bull markets.

Via The Motley Fool

Baby Formula Blues Hit Abbott Laboratories Stock Hard in 2022. Can It Rebound in 2023? ↗

February 07, 2023

The healthcare stock fell 22% last year.

Via The Motley Fool

2 Beaten-Down Stocks With Stable Dividends to Buy In 2023 ↗

February 04, 2023

You can bet the farm on these companies' dividends.

Via The Motley Fool

3 Unstoppable Dividend Stocks to Buy in February ↗

February 04, 2023

All three belong to the elite group of stocks known as Dividend Kings.

Via The Motley Fool

2 Top Dividend Growth Stocks to Buy in February ↗

February 01, 2023

They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace.

Via The Motley Fool

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

52 53 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.